Affiliation:
1. Schools of Pharmacy
2. Medicine, University of California, San Francisco, California
Abstract
ABSTRACT
Variability in valacyclovir bioavailability and the potential for cephalexin-valacyclovir interaction were evaluated. The intraindividual acyclovir area under the concentration-time curve (AUC) varied minimally, whereas interindividual differences were substantial. Coadministration of the human peptide transporter 1 (hPEPT1) substrates valacyclovir and cephalexin minimally reduced the acyclovir AUC. These results suggest a stable valacyclovir absorption phenotype, significant interindividual variability, and minimal interaction between these hPEPT1 substrates.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference12 articles.
1. Balimane, P. V., I. Tamai, A. Guo, T. Nakanishi, H. Kitada, F. H. Leibach, A. Tsuji, and P. J. Sinko. 1998. Direct evidence for peptide transporter PEPT1-mediated uptake of a nonpeptide prodrug, VACY. Biochem. Biophys. Res. Commun.250:246-251.
2. Chu, X., G. P. Sanchez-Castano, K. Higaki, D. Oh, C. Hsu, and G. L. Amidon. 2001. Correlation between epithelial cell permeability of CPX and expression of intestinal oligopeptide transporter. J. Pharmacol. Exp. Ther.299:275-282.
3. Dantzig, A. H., and L. Bergin. 1990. Uptake of the cephalosporin, CPX, by a dipeptide transport carrier in the human intestinal cell line, Caco-2. Biochim. Biophys. Acta1027:211-217.
4. de Vrueh, R. L., P. L. Smith, and C. P. Lee. 1998. Transport of l-valine-ACY via the oligopeptide transporter in the human intestinal cell line, Caco-2. J. Pharmacol. Exp. Ther.286:1166-1170.
5. Ganapathy, M. E., W. Huang, H. Wang, V. Ganapathy, and F. H. Leibach. 1998. VACY: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem. Biophys. Res. Commun.246:470-475.
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献